Background: Soy products contain high levels of genistein, a phytoestrogen that is a potent inhibitor of cell proliferation and angiogenesis. Genistein has been found to inhibit the growth of carcinogen-induced cancers in rats and human leukemia cells transplanted into mice. The induction of stress proteins (e.g., glucose-related proteins and heat shock proteins) in tumor cells has been shown to protect them against programmed cell death; this stress response is inhibited by genistein. The mechanism(s) by which genistein affects certain stress response genes was explored in this study. Methods: Mammalian cell cultures were treated with azetidine, a proline analog, which elicits a stress response that includes the induction of the expression of glucose-regulated protein GRP78 and heat shock protein HSP70. The effects of azetidine and/or genistein treatment on cellular levels of grp78 and hsp70 messenger RNAs and proteins were measured by northern blot hybridization and western blot analyses, respectively, and the binding of nuclear factors to sequence motifs in the upstream (promoter) regions of these two genes were examined by electrophoretic mobility shift assays. Results: Genistein antagonized the binding of a specific transcription factor, nuclear factor-Y/CCAAT binding factor (NF-Y/CBF), to the CCAAT sequence element most proximal to the transcription start sites in the hsp70 and grp78 promoters; this CCAAT element was previously shown to be necessary for full-stress inducibility of both genes. Treatment of cells with genistein converted NF-Y/CBF into a nonbinding, transcriptionally inactive form. Implication: The anticancer effects of genistein may be related to its ability to reduce the expression of stress response-related genes. [J Natl Cancer Inst 1998;90:381-8]
The much lower risk of breast, colon, and prostate cancers in Asians who consume 20-50 times more soy per capita than Americans (1) has raised the question whether compound(s) in the soy diet may be acting as a natural chemopreventive agent (2) (3) (4) . Soy products such as tofu contain high levels of several isoflavonoids including genistein, which has been identified as a potent inhibitor of cell proliferation and in vitro angiogenesis (5) , with antioxidant properties (6) . Furthermore, studies using animal models of cancer showed that both a soy diet and dietary genistein itself may confer a protective effect on mammary, colon, and skin tumors (7) . Strikingly, administration of genistein to female newborn rats has been reported to markedly delay the onset of mammary cancer following carcinogen treatment at day 50 after birth (8) .
Since the discovery in 1987 that genistein is a potent inhibitor of tyrosine kinase activity in mammalian cells, it has been used extensively to explore tyrosine phosphorylation events in signal transduction pathways in basic science studies (9) . The growth of human B-cell precursor leukemia cells in a mouse model system was inhibited by targeting genistein to a B-cell-specific surface receptor with a monoclonal antibody against the specific receptor. The genistein immunoconjugate bound with high affinity to the B-cell precursor leukemia cells, selectively inhibiting the tyrosine kinase(s) associated with that cell surface receptor, and apoptotic cell death was observed (10) . Despite these important advances, the physiologically relevant targets of genistein and the mechanism(s) by which genistein exerts its effect of action are not well understood.
The mammalian stress response represents a defense mechanism that allows cells to respond to adverse physiologic or metabolic conditions that threaten their survival. These stress conditions include viral infections, inflammations, imbalance of ions or other metabolites, deprivation of essential nutrients or oxygen, and the onset of carcinogenesis. Cells respond to these assaults by inducing the synthesis of a specific set of proteins referred to as stress proteins. Examples are the heat shock proteins (HSPs) and the glucose-regulated proteins (GRPs) (11) (12) (13) . HSPs and GRPs are evolutionarily conserved proteins. The HSPs and GRPs belong to a class of proteins known as molecular chaperones, since they can assist in protein folding and assembly. While the HSPs are cytoplasmic proteins that can translocate to the nucleus during heat stress, the GRPs are Ca 2+ -binding chaperones localized in the endoplasmic reticulum. High levels of HSP and GRP expression have been reported in chemically and virally transformed cells and various tumors (14) (15) (16) . In a panel of rat colon adenocarcinoma clonal cell lines, tumorigenicity and immune resistance appear to be associated with overexpression of GRP94 (17) . In human breast carcinoma cells, GRP94 has also been found to stabilize a transmembrane glycoprotein p185 erbB2 , which has intrinsic tyrosine kinase activity (18) . The induction of HSPs and GRPs has also been linked to resistance against chemotherapy, photodynamic therapy, radiation therapy, and apoptosis (15, (19) (20) (21) (22) (23) (24) . Antisensemediated suppression of GRP78 (also known as BiP) induction in tumor cells reduces resistance to cell-mediated cytotoxicity (25) . In a mouse model, suppression of GRP78 induction in these tumor cells results in increased apoptosis and inhibition of tumor progression (26) . Furthermore, patients with breast cancer whose tumors exhibit low HSP70 expression have more favorable outcomes in terms of both overall and disease-free survival (27) . Collectively, these studies indicate that elevated levels of HSPs and GRPs may confer protection against apoptosis; thus, simultaneous suppression of the induction of these stress proteins in precancer and tumor cells could offer a novel approach to cancer therapy. One strategy is to search for pharmacologic agent(s) that specifically interfere with their stress induction.
The induction of GRP78 and HSP70 is primarily regulated at the transcriptional level (11, 12) . Depending on the target of the damage caused by the stress, the two sets of stress proteins can be induced simultaneously, reciprocally, or individually (28) . For example, treatment of cells with azetidine, a proline analog that leads to the formation of malfolded proteins both in the cytoplasm and endoplasmic reticulum, transcriptionally activates both grp78 and hsp70 genes. Thus, azetidine is useful as a stress inducer for testing pharmacologic reagent(s) that can simultaneously suppress the expression of both sets of stress proteins. Genistein has been previously shown to prevent the induction of GRP78 by thapsigargin, a tumor promoter (29, 30) , and the induction of HSP70 by heat shock (31) . In this study, we tested directly whether genistein can simultaneously interfere with the azetidine-mediated stress induction of both HSP70 and GRP78. Furthermore, the mechanism(s) by which genistein affects the expression of GRP78 and HSP70 was explored.
Materials and Methods

Cell Cultures and Treatment Conditions
The K12 cells were Chinese hamster lung fibroblasts [from J. A. Melero (32) ]. The NIH3T3 cells were mouse embryo fibroblasts obtained from the American Type Culture Collection (Rockville, MD). The culture conditions for K12 and NIH3T3 cells have been described (30) . To test the effects of genistein and azetidine, cells were grown to 80% confluence and then preincubated with 140 M genistein (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD) for 15 minutes in fresh medium prior to the addition of 5 mM azetidine (Sigma Chemical Co., St. Louis, MO). After 16-20 hours of drug treatment, the cells were harvested for the extraction of RNA, nuclear protein, or the preparation of total cell lysate.
Northern Blotting
Total cellular RNA was extracted using RNAzol™ B (Tel-Test, Inc., Friendswood, TX). Ten micrograms of RNA was loaded onto 1% agarose-2.2 M formaldehyde gels, and northern blot hybridizations were performed as previously described (30) . The complementary DNA (cDNA) probe used for the detection of grp78 transcripts has been described (30) . Radiolabeled plasmids containing hsp70 cDNA [PMAN 70, from R. Morimoto (33) ] and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (34) were used for detection of their respective transcripts. The level of transcripts was quantitated by the use of a phosphoimaging machine (Molecular Dynamics, Sunnyvale, CA). The northern blot analysis was repeated three to five times.
Nuclear Extraction and Electrophoretic Mobility Shift Assays
Simplified nuclear extracts from K12 and NIH3T3 cells were prepared using methods described previously (35) . Conditions and procedures for electrophoretic mobility shift assays and the addition of antibodies in the reaction mixtures have been previously described (35) . The sequences of the double-stranded synthetic random oligomer used in competitions are as follows:
upper strand, 5Ј-CTCGATGTATGCATCTGATTACTATCGACT-AGCTTGCTACG-3Ј lower strand, 5Ј-GTCGACCGTAGCAAGCTAGTCGATAGTAAT-CAGATGCATACA-3Ј.
Transient Transfection
Conditions for transfection of NIH3T3 cells have been described (36) . The reporter gene constructs used were as follows: (−1290)CAT containing 1290 base pairs (bp) of the rat grp78 promoter sequence directing the expression of the chloramphenicol acetyltransferase (CAT) gene (37) ; the 78C1CAT, previously referred to as (−109/−74)MCAT containing two copies of the rat grp78 promoter subfragment spanning −109 to −74 fused to the minimal promoter of the mouse mammary tumor virus (38) ; and the hsp70 CAT plasmid containing 191 bp of the human hsp70 promoter [from B. Wu (33) ]. The expression vector NF-YA29, which contains a mutated form of NF-Y and is able to negate specifically NF-Y activity, has been described (39, 40) . In addition to the test plasmids, all transfection reaction mixtures contained 3 g CMV␤gal plasmid that contains the cytomegalovirus promoter directing the expression of the ␤-galactosidase gene or 5 g SV40␤gal plasmid that contains the simian virus 40 promoter directing the expression of the ␤-galactosidase gene. The ␤gal plasmids served as internal controls for measuring the efficiency of the transfections. The CAT activities were measured after normalization to the ␤-galactosidase activities. Each transfection experiment was repeated independently two to six times.
Western Blot
For the detection of the CBF-A subunit, 30 g of simplified nuclear extracts from K12 cells was resolved on a denaturing sodium dodecyl sulphate-10% polyacrylamide gel and transferred onto Hybond nitrocellulose membrane (Amersham Life Science Inc., Arlington Heights, IL). The membrane was blocked with 5% dry milk (Bio-Rad Laboratories, Hercules, CA) in the TBS buffer (20 mM Tris-HCl [pH 7.5] and 14 mM NaCl) overnight at 4°C prior to the incubation with the polyclonal rabbit anti-CBF A subunit peptide antibody (35) for 2 hours at 4°C. The secondary antibody used was goat anti-rabbit conjugated to horseradish peroxidase and diluted 1:3000 in the TBS buffer. The immunocomplexes were detected with the Enhanced Chemiluminescence (ECL) Kit (Amersham Life Science Inc.).
For the detection of the stress proteins, 30 g of NIH3T3 whole-cell lysates prepared as described previously (26) were separated on a denaturing sodium dodecyl sulfate-8.5% polyacrylamide gel, blotted onto Hybond nitrocellulose membrane and blocked with 5% dry milk as described above. For detection of GRP78, the membrane was first incubated with a rabbit polyclonal anti-GRP78 antibody (StressGen, Victoria, British Columbia, Canada) at 1:3000 dilution in the TBS buffer, then with horseradish peroxidase-conjugated goat anti-rabbit antibody diluted at 1:3000 in the TBS buffer. For detection of ␤-actin, the primary antibody used was a mouse monoclonal anti-␤-actin antibody (Sigma Chemical Co.) at 1 : 5000 dilution, and the secondary antibody was a sheep anti-mouse antibody at 1 : 3000 dilution. All secondary antibodies were purchased from ICN Pharmaceuticals, Inc., Costa Mesa, CA. Both GRP78 and ␤-actin immunocomplexes were detected with the ECL kit. For detection of HSP70, the primary antibody used was an alkaline-phosphatase conjugated mouse monoclonal anti-HSP70 antibody (StressGen) at 1:500 dilution. The HSP70 immunocomplex was detected with the Immun-Star Chemiluminescent kit (Bio-Rad Laboratories).
Results
Treatment of mammalian cells with 5 mM azetidine simultaneously induced grp78 and hsp70 messenger RNAs (mRNAs). For example, in the hamster K12 lung fibroblast cell line, the grp78 and hsp70 mRNA levels were induced approximately ninefold and sevenfold, respectively ( Fig. 1, A) . Genistein by itself did not affect the basal level expression of grp78 and hsp70 mRNAs. However, in cells pretreated with genistein, it reduced the grp78 and hsp70 mRNA induction level to about twofold and 1.2-fold, respectively, above the basal level. In both stressed (i.e., azetidine-treated) and nonstressed cells, genistein did not affect the steady-state level of the GAPDH mRNAs. For grp78 mRNA induction in K12 and other mammalian cell lines such as NIH3T3, the median is 9.5-fold, with ranges from sevenfold to 11-fold; for hsp70 mRNA induction, the median is eightfold, with ranges from fivefold to 14-fold. The level of GRP78 and HSP70 proteins induced by azetidine was also suppressed by genistein to near basal level (Fig. 1, B) .
Using transient transfection assays, we next determined whether genistein exerts its inhibitory effect through the grp78 and hsp70 promoter sequences. As shown in Fig. 2 , treatment of cells with azetidine resulted in an increase in the grp78 and hsp70 promoter activities by about 11-fold and eightfold, respectively. The promoter activities in these assays were measured by the amount of conversion of chloramphenicol to its acetylated forms. In nonstressed cells, the grp78 and hsp70 promoter activities were minimally affected by genistein treatment. In cells pretreated with genistein prior to the addition of azetidine, the grp78 and hsp70 promoter activities were reduced to less than 1.5-fold of the level observed in nonstressed cells. With the grp78 reporter gene containing only 457 bp of the grp78 promoter sequence, the median induction level by azetidine is 6.7-fold, with ranges from 4.5-to 8.6-fold. With the hsp70 reporter gene, the median induction level is 6.3-fold, with ranges from fourfold to 15-fold. Further analysis of a series of grp78 promoter deletion mutants ranging from 1290 to 85 bp (37, 41) showed that the azetidine induction and genistein inhibition required primarily 154 bp of the grp78 promoter sequence (our unpublished results). Moreover, tandem inverted copies of a subfragment of the rat grp78 promoter, spanning −109 to −75, when linked to a heterologous mouse mammary tumor virus promoter (38, 42) , exhibited a 16-fold induction by azetidine (Fig. 3) . Furthermore, genistein can suppress the azetidinemediated induction of activity of the promoter subfragment spanning −109 to −75 in addition to that of the 1290-bp grp78 promoter fragment as shown in Fig. 2 . The sequence of this grp78 promoter subfragment is shown in Fig. 4 and is referred to as the 78C1.
Mutational analysis of the grp78 promoter reveals that 78C1, which contains the most proximal CCAAT motif and a lowaffinity binding site for a multifunctional nuclear transcription factor Yin-Yang 1 (YY1), is a crucial control element and is conserved between the human and rat grp78 promoter (35, 42) . For stress induction of grp78, regulatory factors, such as YY1 that binds the evolutionarily conserved grp core sequence spanning −170 to −135 (36) , have to act through 78C1 at −90 to exert their stimulatory effects (Fig. 4) . The multimeric CCAAT binding protein CBF, also referred to as NF-Y, binds to 78C1 and transactivates the promoter in a Ca 2+ -dependent manner (42) . Multiple forms of stress-activated transcription of the hsp70 promoter, including treatment with azetidine, are mediated by the heat shock element at −100; in addition, maximal induction also requires functional basal elements, such as the 70C1 element at −65 (43, 44) . While the heat shock factor has been firmly established as the factor that binds the heat shock element and transactivates the hsp70 promoter, several human CAAT binding proteins, including the 52-kd CTF/NF-1 (45), a novel 114-kd CBF (46) , and recombinant CBF/NF-Y (47), have been implicated as transactivating factors that bind at the 70C1 site.
There is considerable sequence and organizational divergence between the grp78 and hsp70 promoters, with the exception that both promoters contain a CCAAT motif immediately upstream of their TATA elements (41) . Furthermore, since 78C1 is sufficient to confer the azetidine response, this prompted us to resolve the identity of the 70C1 binding factor from nuclear extracts, since it may provide a clue to the simultaneous sup- 
Protein blots were probed with antisera against GRP78, HSP70, and ␤-actin used as loading control. pression of both promoters by genistein. Closer examination of the 78C1 and 70C1 sequences revealed that while the CCAAT motif for the hsp70 promoter is in the reverse orientation, the flanking sequences of 78C1 and 70C1 share similarities (Fig. 4) . For example, the 3Ј GC-rich sequence motif previously identified as important for high-affinity CBF/NF-Y binding in 78C1 (35) is also present in 70C1. To test whether CBF/NF-Y binds both 78C1 and 70C1, electrophoretic mobility shift assays were performed. Nuclear extracts were prepared from both NIH3T3 and K12 cells. With the radiolabeled synthetic double-stranded oligomer 70C1 as a probe, a prominent complex (complex I) was formed with either nuclear extract (Fig. 5) . A 10-or 20-fold molar excess of the unlabeled 78C1 was equally effective in inhibiting the formation of complex I as 70C1, whereas a random oligomer showed no effect. In reciprocal experiments, both 78C1 and 70C1 competed efficiently for the 78C1 complex (our unpublished results). These combined results indicate that the major factor that binds to 70C1 as complex I can also bind 78C1.
To further resolve the identity of complex I, the complexes formed with radiolabeled 78C1 and 70C1 probes were directly compared in electrophoretic mobility shift assays. As shown in Fig. 6 , the complexes formed with both NIH3T3 and K12 nuclear extracts migrated near identically in gel electrophoresis, suggesting that their composition may be highly similar. On addition of an antibody specific for the subunit A of CBF, the migration of both complexes was greatly retarded. This retardation was not observed with the preimmune serum. These results suggest that the antibody against CBF was able to bind to the 78C1 and 70C1 complexes and shift their electrophoretic mobility to a slower migrating form. Thus, the major factor from nuclear extracts that binds 78C1 and 70C1 is the multimeric CCAAT binding protein, CBF/NF-Y, or closely related to it immunologically.
To test that CBF/NF-Y is required for the full stress inducibility of the grp78 and hsp70 promoters, we used a mutant form of NF-Y/CBF, referred to as NF-YA29, which has been used in transient transfection assays to specifically block NF-Y/CBF activity (40) . NF-YA29 is derived from the NF-Y A subunit in which three amino acids in the DNA binding domain have been mutated, while it forms a complex with NF-YB, this complex was functionally inactive (39) . Thus, NF-YA29 sequestered the other functional subunits of NF-Y into transcriptionally inactive complexes, acting in a dominant negative manner to block the endogenous NF-Y/CBF activity. By varying the amount of NF-YA29 used in the transient transfection experiments, an optimal dosage of NF-YA29 was determined so that it could inhibit specific promoter activity but affect minimally general cellular transcription (our unpublished results). Under such conditions, we observed that it reduced the stress inducibility of both grp78 and hsp70 promoters and has no effect on the simian virus 40 promoter (Fig. 3) .
Having established that genistein can drastically reduce azetidine induction of both grp78 and hsp70 and that CBF/NF-Y, a common factor shared by both promoters, is required for full azetidine inducibility for both promoters, we next investigated whether CBF/NF-Y is a target for the inhibitory effect of genistein. Nuclear extracts were prepared from untreated (i.e., control) cells, from cells treated with genistein or azetidine alone, and from cells treated with both genistein and azetidine. The electrophoretic mobility shift assays were performed using either 78C1 or 70C1 as a probe. As shown in Fig. 7 , A, prior to azetidine treatment, complex I was formed with both probes. After azetidine treatment, there was a slight but detectable increase in CBF/NF-Y binding. Treatment of cells with genistein alone greatly inhibited complex I formation; in samples from cells treated with both genistein and azetidine, the intensity of complex I was much reduced. This was observed with both the 78C1 and 70C1 probes. Genistein differentially affected the binding of specific factors to their sites. In the case of 78C1, darker exposure of Fig. 7, A, showed that, in addition to complex I, complexes II and III were also formed. Quantitation by laser densitometry of the band intensities of complexes I, II, and III in Fig. 7, B (lanes 3 and 4) revealed that genistein inhibited the formation of complexes I and II in azetidine-treated cells by approximately 70% and 95%, respectively, whereas the formation of complex III was not affected. Thus, genistein preferably antagonizes complexes I and II. Previously, we discovered that the transcription factor YY1 can bind to a site 3Ј to the CCAAT motif on 78C1, and complex II has been identified as a YY1 complex (42) . The YY1 binding site is absent in 70C1. Thus, in electrophoretic mobility shift competition assays, 70C1 was unable to compete for complex II (Fig. 7, C) . Complex III, as in the case of complex II, is specific for 78C1 and is not shared with 70C1. Analysis with other transcription factor binding sites confirmed that the genistein effect is selective for specific factors (our unpublished results).
To determine whether the loss of DNA binding activity of complex I is related to changes associated with CBF/NF-Y, the nuclear extracts used in the binding assays (Fig. 7, A) were resolved by gel electrophoresis and subjected to western blot analysis with a peptide antibody against the A-subunit of CBF (Fig. 8) . Two forms of CBF-A, with an expected size of about 40-kd, were observed. In the control cells, CBF-A existed in two forms, with the upper form being more abundant. In cells treated with azetidine, CBF-A existed predominantly as the upper form. In cells either treated with genistein alone or in combination with azetidine, the upper form was reduced, with the appearance of more lower form of CBF-A. Thus, a reduction in CBF/NF-Y DNA binding activity in cells treated with genistein is associated with a reduction of the amount of the CBF-A upper form.
Discussion
Genistein is a natural component of the diet of Chinese and Japanese who are at low risk for breast, colon, and prostate cancers. In this study, we identified genistein as a potent inhibitor of GRP78 and HSP70 induction in cell cultures treated with azetidine. Since GRP and HSP stress proteins have been implicated in the protection of cells against apoptosis (16, 21, 22, 24, 26, 48) , the simultaneous suppression of their induction in precancer and cancerous cells could be a contributing factor to the anticancer effects of genistein.
We further demonstrate here that the molecular mechanism whereby genistein exerts its inhibition is through interference of a key common transcription factor, CBF/NF-Y, binding to the most proximal CCAAT site of the hsp70 and grp78 promoters. Through the use of the dominant-negative mutant of CBF/NF-Y in transfection assays, we provided evidence that this CCAAT binding factor is required for full stress inducibility of both the . 6 . Effect of anti-CBF antibody on the formation of complex I. Electrophoretic mobility shift assays using the NIH3T3 or K12 simplified nuclear extract with radiolabeled 78C1 or 70C1 as probes were performed as described in hsp70 and grp78 promoters in mammalian cells. Our results are consistent with an earlier report that recombinant CBF/NF-Y binds 70C1 in vitro (47) . Since CBF/NF-Y is a heteromeric factor consisting of at least three subunits, all of which are necessary for stable DNA binding (49) , the interaction of this multimeric factor to 70C1 could not have been detected through expression library screening or southwestern blotting that was used in the earlier isolation of the 114-kd CBF (46) . Furthermore, in transient transfection assays, the 114-kd CBF was able to transactivate the hsp70 promoter, but it had a suppressive effect on the 78C1 element (41, 46) . Our studies also provided an explanation for the earlier observation that genistein did not affect the binding of the heat shock factor to the heat shock element on heat shock; it nonetheless blocked the heat shock response (31) . Thus, by inhibiting the binding of CBF/NF-Y to 70C1, genistein can inhibit the heat shock response independent of the heat shock factor binding to the heat shock element. These results further point to the selectivity of the inhibition by genistein of specific binding of mammalian transcription factors to sequence elements in gene promoters, and it will be interesting to identify other physiologically relevant targets of genistein linked to gene regulation. For example, the antiproliferative effects of genistein may very well be effected through interference of other target genes related to cell growth and differentiation.
How might genistein regulate the DNA binding property of CBF/NF-Y? We found that genistein, when added to the nuclear extract, has no effect on the formation of complex I in electrophoretic mobility shift assays (our unpublished results), thus it is unlikely that genistein directly binds CBF/NF-Y and alters its DNA binding property. As a protein kinase inhibitor, genistein can directly or indirectly affect the DNA binding property of CBF/NF-Y through phosphorylation modification. In our analysis, we observed that the A subunit of CBF/NF-Y in rodent and human cells exists in two forms. The disappearance of the upper form directly is associated with the loss of DNA binding activity. In genistein-treated cells, western blot analysis of CBF-A revealed that the upper form was also reduced compared with control or azetidine-treated cells. The formation of the CBF/ NF-Y complex with either 78C1 and 70C1 was much reduced in the same nuclear extracts. It remains to be determined whether genistein, through inhibition of phosphorylation of the A subunit of CBF or other additional subunits, converts it into a nonbinding and transcriptionally inactive form.
Last, how suitable is genistein as a pharmacologic agent to suppress simultaneously the stress response related to expression of GRP and HSP? Genistein has several distinct advantages. First, it is a natural component of soy protein. Quercetin, a bioflavonoid present in fruits and vegetables, interacts with the heat shock factor and inhibits the induction of heat shock proteins (31); however, it will be without effect on the glucoseregulated protein-mediated stress response. Second, genistein, even at high concentrations (200 M), appears to have no toxic effects on confluent, quiescent mammalian tissue culture cells (5) . Although in this study the experiments were performed with 140 M of genistein as used in previous studies (29, 30) , the half maximal concentration for the inhibitory effect of genistein on azetidine induction is around 40 M (our unpublished results). This compares with 18.5 M, the reported genistein concentration in humans that is physiologically attainable (7) . Furthermore, it is possible that there are other isoflavonoids or components in soy products that can complement genistein in regulating gene expression and contribute to its putative chemopreventive effect. Genistein does not affect the basal expression of GRP78 and HSP70 in nonstressed cells, a likely explanation is that other transcription factors that interact with these promoters can functionally substitute for CBF/NF-Y to maintain a low basal level expression (41, 43, 50) . More important, in the mouse model, administration of genistein immunoconjugates does not induce systemic toxicity (10) . Third, CBF/NF-Y also binds and activates the grp94 promoter (51), so genistein should also in- Fig. 7 . Effect of genistein on CBF binding activity. A) Simplified nuclear extracts were prepared from untreated K12 cells, from cells treated with 5 mM azetidine or 140 M genistein, or both. The electrophoretic mobility shift assays were performed using either the radiolabeled 78C1 or 70C1 as probe. The autoradiogram is shown. The positions of complex I and the free probe are indicated. B) Darker exposure of the autoradiogram shown in (A) with the 78C1 probe to show the effect of genistein on the minor complexes II and III. C) Simplified nuclear extract prepared from untreated K12 cells was used in electrophoretic mobility shift assays to test for binding specificity of complexes I, II, and III. The probe used was radiolabeled 78C1. The reaction mixtures contained either the probe alone (probe), no competitors (-), or increasing amounts (25-and 50-fold molar excess) of competitor 78C1 or 70C1 as indicated on top. The autoradiogram is shown. The positions of complexes I, II, and III, and the free probe are indicated. hibit the stress induction of GRP94, which is associated with enhanced tumorigenicity and immune resistance in colon adenocarcinoma cell lines (17) , and stability of p185 erb2 , a tumor marker in breast cancer (18) . Fourth, genistein has previously been shown to prevent the induction of GRP78 by thapsigargin, a tumor promoter (29, 30) , and the induction of HSP70 by heat shock (31) , suggesting that the mechanism of genistein inhibition can be applied to multiple forms of stress. Previously, molecular approaches, such as antisense or targeted ribozyme vectors, have been used to suppress the stress gene expression in tissue culture cells (26, 52) . Genistein, used either intravenously as a targeted immunoconjugate for immediate therapeutic effects or orally as long-term dietary supplements, offers an alternative, pharmacologic approach for the suppression of the mammalian stress response. The effectiveness of genistein as an anticancer agent in humans awaits further preclinical, clinical, and epidemiologic testing.
